Total trials
182
Active
23
Phase 3
19
Total enrollment
28,296
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| EPA | — | — | — | — | — | 1 | |
| DHA | — | — | — | — | — | 1 | |
| The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks | — | — | — | — | — | 1 |
Next readouts
- 2025-07-31
- 2027-08-01
Top conditions
- Obesity62
- Overweight10
- Overweight and Obesity10
- HIV10
- Weight Loss9
- Smoking Cessation6
- Physical Activity5
- Sleep5
Frequently asked questions about The Miriam Hospital
- How many clinical trials does The Miriam Hospital have on ClinicalTrials.gov?
- The Miriam Hospital is listed as the lead sponsor on 182 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The Miriam Hospital's trials are in Phase 3?
- 19 of The Miriam Hospital's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does The Miriam Hospital focus on?
- The Miriam Hospital's most-studied conditions on ClinicalTrials.gov are Obesity, Overweight, Overweight and Obesity, HIV, Weight Loss.
- When are The Miriam Hospital's next clinical trial readouts?
- The Miriam Hospital has 2 upcoming primary-completion readouts tracked here; the soonest is “Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community”, expected around 2025-07-31.